MyoKardia (MYOK) 7 Aug 192019 Q2 Earnings call transcript

Good day, ladies and gentlemen and welcome to MyoKardia’s Second Quarter 2019 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to introduce Michelle Corral. Please go ahead.

Thank you so much, Andrew. Good afternoon and thank you all for joining us for today’s call. MyoKardia’s Corporate Corral, Relations. and Michelle am Head Communications of Investor I portfolio. we quarter and recent our second be upcoming results across Today, reviewing as financial will as well milestones progress

was The issued available second our website. results quarter press on earlier afternoon and financial this is release

Edelberg, call Harris, Jay our Officer. SVP today’s Chief by CEO, is Gianakakos. Development MyoKardia’s Financial Tassos Leading of joined Clinical is Tassos Dr. our Taylor and

the will line our Following be for question. for yourselves their will prepared that Bauer, Officer remarks, to which segment, that note Chief Please open Business Q&A we also we joining. Jake one the you Q&A during ask limit

law. As a no update new cause or company’s by as include the information view future to required these will reminder, could as statement information that our revise as of or any to obligation or statements. those implied call with by to expressed forward-looking press well X, the concerning the filings to except undertake Please discussed this SEC for differ materially today, actual release reflect factors as from statements, We represent during refer forward-looking which August events, information results XXXX. risk today’s

now like hand over would CEO. call Tassos? to I our to the

potential energizing all to close of for just market NDA-related the ever to MyoKardia HCM. company’s therapy days, screening activities. afternoon, HCM. really our of key the to timeline prep be us we and new our obstructive Good our year and of first introduction enable drug for within pivotal our and us could in how today. on joining results finished the application mavacamten to allowing With EXPLORER us first at have incredibly is and Michelle. planning full Thanks, of everyone to of completed submission to from now thanks filing are for completion It’s development for targeted MyoKardia within first a we and registration now program, trial sharpened enrollment that consider in

set disease. HCM care limited and the progressive approaches Getting that and symptoms that disease to a some treat to over treatment patients disease have only function, also that’s symptoms incredible They condition this XXX,XXX really the Physicians the that affects achieve. one to only how are Americans patients can in debilitating a manage have options of and slowdown we in time. life. don’t with actually and the needed available much new in reduce and progression is they to potential with underlying an manage prime a one physicians, in of some exactly out would but patient reverse advancement or be not improve what complex

leader in the treatment the is MyoKardia science HCM. and of the

line study, data launch positive in and guidance our to second NDA submission compared effects to is half schedule, top if released scientific in pipeline science understanding invest Our their supporting with and clinical disease specifically our the HCM, of continue them. on in focused people company has the platform EXPLORER knock-on of patients on approved and the the staff Based their is and we ahead who in to which hard the of trial And enthusiasm XXXX investigators and participated families the our team, second the those accelerating HCM. of XXXX, the on for broadest subsequent work quarter that and of enrollment previous timing. care

top value patients to de-risking line got in across have enrolled as weeks today patients. of screening share closed we XXX enrolled accelerated patient few creating of the now next remaining the results, XXX pipeline. a over to our our more than screening back several We be with and multiple final and have new and within few days. It’s target datasets Between EXPLORER

the from Cardiology been accepted European PIONEER-OLE mavacamten Paris have and for obstructive Congress data place in at OLE the Annual the for presentation taking data Philadelphia at in in taking month of at XX-week November. Society XX-week end been of this for presentation HCM, Specifically American place have Meeting in Association accepted Heart

far encouraging changes with would increase important XX to mavacamten results weeks volume and XX-week the evidence EXPLORER in durability data has confidence the prime. in supporting successful E/e’ provided and outcomes, further that OLE including mavacamten’s study. a So improved XX our and seen index safety NT-proBNP, over over and LA biomarkers correlate timeframe Similar

top one the release indication on MyoKardia, the are and to in announced second we data track Looking of X May at non-obstructive a quarter. Phase MAVERICK in important fourth enrollment and completion for HCM line in mavacamten very study

about the well with a failure, syndrome later address Americans. X.X call more defined MAVERICK this to therapies how help as which appropriate results expect affects that move dose and studies talk could will We enable Jay as the registration into estimated an on of to as heart be diastolic us doses, million disease. success MAVERICK identification MyoKardia approved successful mavacamten the no non-obstructive will with or

molecule on Beyond program mavacamten, candidate, patients our commitment underscoring leadership is in distinct set HCM month. through studying begin healthy of is in a our to possesses XXX portfolio pharmaceutical dosing that area novel this that properties MYK-XXX, volunteers HCM second to potential a we therapies. disease plan

data function. will reduced is year, in contraction systolic X XXX this to of important end cardiac MYK-XXX. intended the we from share increased with patients Before Phase

in thus studying have the clinical and is novel a development the Phase burden. needs X reported in of At indications steps We dysfunction from targeted underlying key in disease be area will XXX profile expect X new the a year. far by fourth with an that encouraged outline include the where best-in-class results treatments. Results will really our quarter XXX this which program, that systolic time, we can important been driver Phase therapy believe of the to next be

Jay would hand of our to the talk to will trials that like overview, on over things I about Jay? and latest With now MAVERICK EXPLORER mavacamten. who

patients coordinators next be the EXPLORER nearing largest study to investigators the obstructive than more our effort several by This landmark as will great collaboration a steering Enrollment contributed study. to and More our clinical development days. today. of trials our everyone. with a what most and participating course well in XX conducted countries comprehensive has is been the randomized Tassos to and in as pivotal completion sites HCM thanks have team committee, in XXX Well, patients in EXPLORER constitute actively patients within enrolled good than afternoon with study enrolling anticipate the XX is we in trial. fully

prioritized the strategically and team to centers higher comprehensive in this HCM recruitment Our retention study. volume enable

with generated enthusiasm myself, the have and promising of clinicians commitment, a demanded the of the their team body believe in the our investigators matched trial amongst EXPLORER excitement this continue I at collecting has study enrollment the visiting to investigator the and We targeted mavacamten. key data MyoKardia’s in and We training execution remarkable and sites for development most efforts been provide our the can a have time the prospect been level conducted staff. the growing and protocol. the HCM successful supported site regular been factor to contact support clinical clinical for organization. by extensive to spent with of engagement attest sites the Having of in of will by by many data be therapeutic wealth The of and by of

what care of caregivers learnings the driven clinical We The of Peak make secondary patients, New data informed HCM. the the with PIONEER-HCM feeling in the associated standalone as most Our the the which their about York serving secondary as obstructive mutations endpoints, these focus these of classification the endpoints In genetic the including components and believe X formation Non-obstructive HCM Association in database cases, well myosin in study. we result exercise in EXPLORER’s execution primary functioning and as VOX Heart on better. study was heart. collect in will reflects same capture response and by selection up of will primary endpoints endpoint result impact and this endpoints. sarcomere, actin both as symptoms. clinicians by both and directly is the mavacamten’s the and These excessive our function Phase cross-bridges mutations continue thickening

and the comes in potential Data at not thickness also our of therefore and that mavacamten’s indicators example PIONEER-OLE from volume the what most believe move effect a are to it endpoints, the closer left of echo to atrial recent size. preclinical biomarker ventricle have NT-proBNP The you occurs us benefit. to dataset will of are HCM. give including ACC heart to plasma evidence maybe encouraging state and gradient and long-term disease, mavacamten and linked several These of left studies directly In presented non-obstructive by observed driven across HCM the positive from of with this the normal and compliance the reason some non-obstructive clinical left diastolic. lower during the lack on disease with symptoms ventricle patients

cardiomyopathy. first and trial concentrations study, concentrations is dosing ml above a approach per the The largest of tolerability. to is trials doses patients receive and randomized non-obstructive endpoint has the Phase clinical MAVERICK of hypertrophic primary once-daily been MAVERICK a in Patients with assigned MAVERICK and the of safety X one to in three dose-ranging groups since some obstructive By in nanograms us picture these of two one to below and fuller dose titration. with with is population to there targeting XXX gradient provide centered XXX no design, placebo. patients target guide around right be or others will this of mavacamten

significance. statistical the plan a study is issue the trial detailing We quarter. release fourth line a designed show during to from to top As this results press the MAVERICK reminder, not

data pursue also medical will at We next presentation of congresses scientific year. these

diseases with New I parameters levels as endpoints class, exercise of MAVERICK a the confident this in function informative that program of demonstrate filling. we wealth The anticipate will registration Among measured the will an protocol the in of improving to our studies York of of life VOX, study. population, and this best assessment and with the non-HCM The mavacamten symptoms of goal the tackle Association via effect and positively to also for feel capacity assessment plasma mavacamten medicines of secondary benefits need be This non-obstructive by provide in indication. HCM on to symptoms is improve and turn and we driven non-obstructive functional measures. how function support other to in highly mavacamten will measured believe us systolic relaxation. provide information of designing be in MAVERICK mavacamten’s Should to echocardiography, late-stage diastolic more effect define is success HCM. compliance we NT-proBNP as the in diastolic intelligence in peak data will changes exploratory be and Heart diastolic generated translational quality the by that team ability from can

only mention will strides MYK-XXX Congress, all present diastolic target informed give and not our as This heart well failure the stuff data from insight data. PIONEER-OLE, and weeks EXPLORER coming the to forward the being known heart, of upcoming no end to will the PIONEER-OLE time ability the in significant With data MyoKardia. in ESC the and next with months, therapeutics generated pipeline. into target improvements to data to exciting you MAVERICK by of treat from at being full being We incredibly the way tremendous trials from and at look the this HFpEF. the month, We filling MYK-XXX an or the MAVERICK as other we to keeping our the look research populations XX is relaxation up us made ahead where

fourth Taylor the quarter. through will second quarter – now results us take

Thanks, Jay.

recent just will our a discussing our the with Before partnership. few Sanofi, transaction highlights which quarter second provide from our of accompanied I conclusion results,

of wind As to which royalty agreement MYK-XXX, on U.S. remaining ranged MyoKardia, an the an part reclaiming million process, on in held down mavacamten interest, we $XX In of currently make XXXX. in in sales exchange we X% the only we of XX% was which acquire to $XX sales will annual of and broader subsequent the interest volume. based a payment Sanofi’s a from middle and reached initial escrow made of payment for million this economic royalty

price purchase stream commercial our to our rights have and for we and HCM this that represents franchise and We able to during been are global, MyoKardia consolidate economic for to believe deal XXXX a great shareholders. royalty the thrilled

the cash confident across program which is are the in of decided positioned we expense reflect we strategic our purposes, third and We why an as our to reduction portfolio. the full opportunity of $XX increase plan our are financials, million control and we optionality in now full to our interest in a consideration for as of P&L ahead and quarter investments. with balance us, economic In

$XX reflects and including towards of R&D approximately MAVA-LTE. a R&D was including MAVERICK, million reimbursement $XX.X were expense. year-over-year reflecting and net mavacamten the In R&D million, our $XX operating driven Now, second studies, of financial turning spend, of late-stage of results, G&A quarter XXXX increase EXPLORER total by approximately This advancement of QX, the $XX.X Sanofi. expenses expense in from $XX.X million million, million of

collaboration second quarter payments our yet to and quarter be association the million royalty With credits the does buyback. of We with the cash this in recognize related investments, will $XXX the which ended the reflect in mavacamten to final with concluded, R&D not program. XXXX

We to fully funded year. runway on the in MYK-XXX and advance for to of the registration our Included the readout activities and ability HCM full are pipeline milestones later following in positive this planned our of execute obstructive the XXXX, program MYK-XXX anticipated data year expected projection more half is EXPLORER. all mavacamten both including into a for aggressively our starting second top than operational line past

far MAVERICK come screening and in the six We’ve and we’ve released month XXXX a enrollment XXXX close. draws and So to months PIONEER-OLE data. in explorer in to completed before

look We to. well study as a progress additional of of from data MYK-XXX, longer-term Phase to significant forward lot data the PIONEER-OLE data will have Xa from as MAVERICK and from

that, I’d open up to the now call So with questions. your to like

here me and Bauer. and are reminder, Edelberg a Tassos with Dr. Jay As Jake

question first line Our Instructions] Suisse. of [Operator Auster you. Credit Martin from Thank comes the with

is now open. line Your

the guys spoken repurchase commercial Mavacamten the last previously Tassos especially fairly potential that. Hey, on range the a broad there you thanks, being and royalty pricing over about progress from about you everybody, for think congratulations quarter, Sanofi.

cause higher if seen payer analyst commissions to of you starting kind or Thanks. by be lower then, community to how closer on wondering could do data And valuable to and/or EXPLORER. beyond forward you’re as pricing in the factors the is will the and the of comps get improvements And commercialization. on the optimistically, would was look EXPLORER exercise update you data towards about general you we pricing that thinking just us swing capacity end I to As range. What think side? communities most data in what

us Hey, we dynamic Marty. right really Yes, where very early are too we context to for much The as thanks. comment all given pricing, know. on now

the creating to focused therapy. the to and going what is think that for us driver that – we’re illustrate on evidence the main is really a this this I ecosystem valuable is is

that to one the and a introducing underlying be first the the of is is cause product, really We’re option. with one talking targeting going disease about disease inadequate area

be that context, let’s from like we ranges outside going value our the of data. a of the standpoint control say, are us So by for to – things out influenced really

at models are of at looking and open-label disease as you totality for the seen to modification disease in we extension. to improvement our in the So disease, program progression beyond see functional primary of are These reversing around we’re looking are potentially that relevant down in know, what and the progression disease. things aims starting symptom we’ve preclinical the improvement slowing that

that, our of be on. to have the able head we ability hang see and the to so are exciting, really more really that’s that to So going

more I potentially ends value we’re patients think is slowing reversing taking majority and as the the that see relatively therapy, progressive life. for these a up of we’ll ultimately what disease down

Thank you. comes the question of with And next line Ritu our from Cowen. Baral

is now line Your open.

for about taking like ventricular open or disease, the is as trial, Hey in measures or wondering sitting burden Thank of thing is kind EXPLORER be death. thing I’ve kind This just patients you arrhythmia you lot biggest – better for of non-sustained and so for in kind risk been those kind the sudden the even of Tushant label One exploring thinking question. burden In is these much my this the about risk guys. cardiac Ritu. studies guys of tachycardia of will well. and extension arrhythmias of of your of VT in the

Jay. is This

question great the at different range a burden with be it’s So overall a there looking we’ll of and modalities. arrhythmia

we about in today out it that is over in left the the we’ll of was – think the size that course to follow and of promising we the AF the continue burden. most I see atrial set time, reported reduction volume know OLE atrial volume left thing correlation that to that’s out

what really seeing. very, very excited So we’re about we’re

our with And Birchenough of line next Jim you. Wells Thank the Fargo. from question comes

Your line open. is now

Yes, PIONEER just New MAVERICK of Question what progress. the hi the guys, classification. relative out study baseline on in peak trying we York in and Association on we characteristics to Heart VOX understand similar congrats to be all of if expectations baseline saw to terms should expect

make saw sure And for either or echo parameters are we then our these looking expectations are exposure of correlations and that patients clinical to we in show Thanks. as to have Just those PIONEER. just plasma benefit want terms similar the in endpoints. that some between of potential

Hey, those the at characteristics can there Jim. baseline the similar team looking Yes, are tell here we so check we and that and MAVERICK and very his straight Jay population away. between PIONEER similar those you are

of which areas, remarks we’ve really this a You an use dimensions which constructed in really give lines of and got touched know have the unmet in is on around potential needs create MAVERICK, have for that helping dysfunction. two on to in folks to those for us to into well diastolic starting important it, mavacamten’s the exciting have planet this along as expansion evidence strong improvements the in diastolic and us as moves like is the are study passed us of it’s the potential patients, biggest may non-obstructive the us be study that remaining one as value prepared

design very enabling the study’s about good feeling success. we’re So and

looks success like be bit it can in about us Jay MAVERICK tell and expect We maybe successful you. for what more to little a

range have PK. a was we’re study, this going because of patients different know, a to dose-ranging at You

get symptomatic, the patients be to the that’s class, going based find and response, the the to dose response what on benefit led functional and be to biomarkers, looking the the profile echocardiogram we’re So is. for most going moving the who of the those that that success

question And you. from next Thank the with comes line Anupam our Rama JPMorgan. of

now Your line is open.

and the Congratulations is in for Anupam. This all taking questions. guys. progress thank Tessa my us Hi on for from you

is and Just we’ve the in NYHA be of than perhaps less one specifically population, you in benefit a and arm HCM can from thinking win population would non-obstructive thinking in magnitude again on view the A. of so there? class this what to us, MAVERICK and in Cohort what guys. How placebo be us remind obstructive kind less you a are seen you could just of about be observe you that about the VOX Thank scenario what than there how a much

we So that when we’re this, no know there reducing. that to gradient be we’re thinking is about going

So we’re in that in component, potential patients non-obstructive HCM. on improving diastolic looking benefits these the for that’s impaired

going see, the totality really improvement on data in the echo the looking we’re to to symptomatic also we component the find from to functional to So of that that focus going hope biomarkers response. placebo those at be and addition to

look. So that’s really we’re going to where

so to that that out dose see totality want right concentration. we And

And Stanley. Hung Jeff question of with line Morgan Thank comes you. from the next our

open. now is line Your

Thanks the question. for taking

last had can For mavacamten you heart year-end? failure what pre-clinical you’re one us what diastolic expecting learning’s can by have and you you data in that from remind apply

really very, hemodynamics in mavacamten. lot and well a of to are understanding mavacamten mutations things the diastolic assessing ongoing can current of affects it from underlying that translational cause we that clinical Learnings that pathophysiology, disease heart, very models, the that Jeff. the our same. and are the the hey, apply physiology a disease our the where the and are understanding with we’re Learning we couple studies How yes, we know dysfunction, we so in of

really in as function to factors a that about well data that us of into bringing diastolic and disease around diastolic So mavacamten’s is learn itself effect and the diastolic on as help it. how repository back relaxation, we’re dysfunction compliance

and I hand. collecting we’re we’re the would insights and is are information the we’re those say in this have that that So, we in really all that studies datasets are of course because in important getting,

for there’s data non-clinical we year, the conferences, the releasing and well that of remaining terms roster of In now between I medical we the on know are as a of that ESC end lining as lot up plan AHA. the the

the look planning on on sharing that be So what out we’re there. for and

from next our of Alethia comes And you. with question the line Fitzgerald. Thank Cantor Young

is line now Your open.

this Emma on Alethia. Hi, is for

increases XX% to Phase saw contractility we believe around X% of in I higher XXX, at For X. cardiac of the exposures

should So just safety any could of in when if the then at we potential we also around key the increasing you we’re Phase context could range looking any be what see X wondering contractility? provide and metrics that

you bet. Yes,

You bet, Emma.

is from that hearing drug a for XXX be valuable us and about. you’ll more candidate So, more us asset

year, segments Phase where lot about will are a to little systolic haven’t a about the update on far, to creating lot so from subsets talking for X talked compared towards we of and it plan plans think we later on to want intended release patients program, to there of year. We and as of get But all more here have there’s we that data that that function, given we’re we great end value this data are to pursue bit we this on patients working several how the that share opportunity. whole We progress into think our about the mavacamten. more our going study we advance targeted ongoing you’re a targeted

that You’ve encouraging accurately the Phase find we from data characterized X.

cardiac and potential stroke the myosin we’re We’re diastolic so volume is activation important. able a output that’s in seeing we the impairing we’re volume, gives to contractility importantly, molecule what seeing improvements XXX to that best-in-class think really increase we’ve without in fact design, stroke and far,

XXXs So that of is a mechanism. signature feature

sharing like referenced well. we’ll share while function data the the So, diastolic information then that in function be you’ve improvements as data around speaks systolic to we

Thanks. That’s helpful.

with Gobind of next our Markets. BMO from Singh question line comes Capital And the

is open. line now Your

is on George on Farmer. This for Hi quarter. Congrats another Gobind guys.

to how secondary if Thank are royalty just why the along going maybe primary, process, enrollment competitive you. many anything details reason are parties, treated then was increased Just in share Was those question a patient be second EXPLORER analysis? any of the two and the there how Sanofi so, in any lines? the could questions. patients and those buyback was you from And

Yeah.

little So, him and about line, we’ll the a Jake Jay maybe is on the second have a bit exceeds. enrollment in answer and the royalty question

So, wanted was opportunity of entered who end to sure robust so into that quite the make at were and screening enroll. the the trial that the to came patients given many screening enrollment really patients we all

So, we’ll the able [indiscernible] to will part protocol be without as secondary any handle those overall as primary difficulty. the handled be of endpoints and it and

a the think, And lot the hopeful there I that community. particular, the acceleration underscores at and new and in The really of numbers of are are for some timing the, from sites. of the think, out patients clinical I the there in patients screening, that’s very therapy. investigators, enthusiasm The a

gratifying that Jay, to And so, it patient in numbers hand it’s from us, let an study. to me over the for more accelerated translate timeframe you. into see

competitive competitive we’re Yes, it feel We full found We sure we receive was believe on excited Sanofi. was. moved when how process, was respect before It monetize in royalty, quickly not was tried but another quickly with back. the We asset. we broad act to a there to to rights to And value do the that out transaction. process. we’ve captured going the there bidder

helpful. you. Thank Very

the And question you. with comes Mohit line next of Bansal our Citigroup. from Thank

Your line is now open.

as my question taking well. for Thanks and from all congrats my the end Great. on progress

was there. you have trial, on so of going be mavacamten wondering, might non-obstructive that part in past the to a CV is discussed why compliance key Just

looking are to in Thank pre-clinical be amount benefit enough compliance the would at you here your do a show witnessing of in work, think the the timeframe you. CV trial. MAVERICK on based we So we are

that we I the the the improvements been even both OLE and biomarkers, So, most is data data gradient we look the that in PIONEER-OLE. relieved. are In we should has after plasma from see echo actually think compelling ACC, at the seeing

those would especially indicator So share to we size, benefits that LA translate a reduction that who the able same diastolic have even into ratings never the reduced, with of non-obstructive indirect be the that, would hope expect is in that the good an they in and we predisposition potential since genetic been volume patients obstruction would had after so HCM.

I’m no And at this time. showing you. questions Thank further

the Gianakakos with So, CEO turn to remarks. back over will I Tassos that, closing call for

such This an MyoKardia. Thanks lot, point Andrew. is interesting a time in for

incredibly are lives can disease starting imagine, to make as a before with energized difference of all have of about serious opportunities the with people HCM. We we meaningful in us you the cardiovascular

Phase from further a X from data the two quarter Phase and process readouts for and launch line than next less MAVERICK. we’re for study potential through important up regulatory and about between we’ve year, in we Now and of gearing mavacamten year X build the pivotal to the commercial away with value now second top in XXX expect today, data talked non-obstructed

upcoming So, everyone to your medical today MyoKardia support over the time on mission. for you see you progress to conferences. and updated the for continued and Thanks month portfolio keeping I our your to look hope and forward of or the of we and investor next our many across so, as of participate several in

or Ladies wonderful may conference. and all in disconnect. you the and day. gentlemen a thank participating program This today’s does you have conclude Everyone,